Wells Fargo analyst Vik Chopra lowered the firm’s price target on Globus Medical (GMED) to $93 from $95 and keeps an Overweight rating on the ...
Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...
Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read ...
BTIG analyst Ryan Zimmerman raised the firm’s price target on Globus Medical (GMED) to $94 from $91 and keeps a Buy rating on the shares after ...
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'd want ...
Q4 2024 Management View CEO Daniel Scavilla highlighted record revenue of $2.519 billion for 2024, driven by $951 million in growth and a 61% increase versus the prior year. Non-GAAP EPS for the year ...
The Globus family of brands has expanded and enhanced its sales team to better serve Canadian travel advisors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback